{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-25-000083","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.804074+00:00","generated_at":"2026-05-17T14:03:20.463419+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025","bullets":["Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.","Revenue $1.3M (up from $0.1M); R&D $22.3M (-67% YoY); G&A $6.4M (-93% YoY).","Cash and equivalents $186.6M at June 30, down from $216.5M at March 31.","Ozekibart (INBRX-109) Phase 2 chondrosarcoma trial fully enrolled; results expected by late Oct 2025.","Initial Phase 2 data for INBRX-106 in head/neck cancer + pembrolizumab expected in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-25-000083","json":"https://secwatch.observer/filing/0002007919-25-000083.json","markdown":"https://secwatch.observer/filing/0002007919-25-000083.md","text":"https://secwatch.observer/filing/0002007919-25-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/0002007919-25-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/inhibrx-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:03:20.463419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}